Fluid Bolus Therapy-Based Resuscitation for Severe Sepsis in Hospitalized Children: A Systematic Review

Ben Gelbart1, Neil J Glassford, Rinaldo Bellomo

  • 11Department of Intensive Care, Royal Children's Hospital, Melbourne, VIC, Australia. 2Melbourne Children's Research Institute, Parkville, VIC, Australia. 3Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia. 4Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

Insights

Limited data support fluid bolus therapy for pediatric septic shock. More high-quality randomized controlled trials are needed to evaluate its effectiveness and optimal use in hospitalized children.

Area of Science:

  • Pediatric critical care medicine
  • Septic shock management

Background:

  • Fluid bolus therapy is commonly used for pediatric septic shock.
  • Evidence supporting its efficacy and optimal protocols is limited.

Purpose of the Study:

  • To systematically review existing data on fluid bolus therapy in pediatric septic shock.
  • To identify gaps in current research.

Main Methods:

  • Systematic review of randomized and nonrandomized studies.
  • Searched Medline, EMBASE, and Cochrane Central Register of Controlled Trials.
  • Included studies on severe sepsis/septic shock, excluding neonatal and specific etiology studies.

Main Results:

  • Analyzed 3 randomized controlled trials and 8 nonrandomized studies.
  • Heterogeneity precluded meta-analysis.
  • No significant physiological differences observed based on fluid bolus volume; no trials compared fluids with vasopressors.

Conclusions:

  • Current evidence for fluid bolus therapy in pediatric septic shock is limited.
  • Urgent need for prospective observational data and randomized controlled trials.
  • Further research required, especially in resource-rich settings.
Abstract

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
657
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
817
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
588
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
762
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
484